In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi U.S. strategy exec

Executive Summary

Sanofi-Aventis names Juergen Lasowski, PhD, to head U.S. business development & strategy. He formerly served as Aventis VP-strategic planning & business and head of strategic development at predecessor company Hoechst Marion Roussel. Lasowski will report to Tim Rothwell, who became Sanofi-Aventis U.S. president following the completion of the merger (1"The Pink Sheet" June 28, 2004, p. 19)...

You may also be interested in...



Aventis U.S. Team Has RPR Execs Heading Commercial Op & Finance

Rhone-Poulenc Rorer Senior VP and General Manager John Leone is heading Aventis' North American Pharmaceuticals commercial operations - sales and marketing.

Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus

Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.

Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.


UsernamePublicRestriction

Register

PS044983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel